Literature DB >> 15710233

Effects of desipramine treatment on tyrosine hydroxylase gene expression in cultured neuroblastoma cells and rat brain tissue.

Meng-Yang Zhu1, Wei-Ping Wang, Ross J Baldessarini, Kwang-Soo Kim.   

Abstract

Activity and expression of tyrosine hydroxylase (TH), the rate-limiting enzyme for catecholamine synthesis, are modified in response to antidepressant-treatment. We examined effects of the selective norepinephrine-transporter (NET) inhibitor antidepressant desipramine (DMI) on expression of TH in human neuroblastoma cells (SK-N-BE[2]M17) and in rat brain regions. TH mRNA levels were determined by Northern blot in vitro, and by in situ hybridization ex vivo; TH protein levels were measured by western blot. Brief exposure of neuroblastoma cells to 0 vs. 5, 50, or 500 nM of DMI had little effect on TH mRNA levels, but exposure to 50 and 500 nM DMI for 14 days increased the mRNA by up to 72%, with a continuous rise from 3 to 14 days of exposure to 500 nM DMI. In contrast, 500 nM DMI led to an initial slight increase, followed by a continuous and sustained decrease in TH protein level by up to 53%, from day 3 to day 14. Daily treatment of rats with DMI (10 mg/kg, i.p.) for 3 or 14 days significantly increased postmortem cerebral TH mRNA in the locus coeruleus (LC) area by 47-68%. Again, TH protein concentrations in LC decreased at 3 and 14 days, by 25-40%, with transient significant reduction in amygdala tissue after 3 days of treatment that were not sustained. These findings indicate that DMI exerts complex, typically opposite and perhaps compensatory, gradually evolving effects on the expression of TH protein (decreases) and its message (increases), possibly in response to increased synaptic availability of NE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710233     DOI: 10.1016/j.molbrainres.2004.10.009

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

1.  Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex.

Authors:  Susan L Erickson; Anjalika R Gandhi; Josephine K Asafu-Adjei; Allan R Sampson; LeeAnn Miner; Randy D Blakely; Susan R Sesack
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-06       Impact factor: 5.176

Review 2.  Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment.

Authors:  Antonio Asensi-Cantó; María Dolores López-Abellán; Verónica Castillo-Guardiola; Ana María Hurtado; Mónica Martínez-Penella; Ginés Luengo-Gil; Pablo Conesa-Zamora
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

3.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

4.  Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.

Authors:  Zaorui Zhao; Alicia M Baros; Han-Ting Zhang; M Danet S Lapiz; Corina O Bondi; David A Morilak; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-04-16       Impact factor: 7.853

5.  Glucocorticoid receptors in the locus coeruleus mediate sleep disorders caused by repeated corticosterone treatment.

Authors:  Zi-Jun Wang; Xue-Qiong Zhang; Xiang-Yu Cui; Su-Ying Cui; Bin Yu; Zhao-Fu Sheng; Sheng-Jie Li; Qing Cao; Yuan-Li Huang; Ya-Ping Xu; Yong-He Zhang
Journal:  Sci Rep       Date:  2015-03-24       Impact factor: 4.379

6.  Effects of chronic social defeat on expression of dopamine β-hydroxylase in rat brains.

Authors:  Yan Fan; Ping Chen; Ying Li; Meng-Yang Zhu
Journal:  Synapse       Date:  2013-03-05       Impact factor: 2.537

7.  CRE/CREB-driven up-regulation of gene expression by chronic social stress in CRE-luciferase transgenic mice: reversal by antidepressant treatment.

Authors:  Ulrike Böer; Tahseen Alejel; Stephan Beimesche; Irmgard Cierny; Doris Krause; Willhart Knepel; Gabriele Flügge
Journal:  PLoS One       Date:  2007-05-09       Impact factor: 3.240

8.  Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Ashley S Harms; David G Standaert; David T Curiel
Journal:  Viruses       Date:  2014-08-21       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.